Patent Assignment
Reel/Frame 025800/0044
Change of Name
Recorded: 2011-02-13
Received: 2011-02-13
Pages: 3
Assignor
MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY
Executed: 2010-11-18
Assignee
MOUNT SINAI SCHOOL OF MEDICINE
ONE GUSTAVE L. LEVY PLACE, NEW YORK, NY, 10029, UNITED STATES
Covered Properties
(34)
Embedded Chimeric Peptide Nucleic Acids for Generation of Induced Pluripotent Stem Cells
Application:
61/417,760 →
Use of Podocan Protein in Treating Cardiovascular Diseases
Application:
12/809,899 →
Methods and Compositions for Inhibiting Autophagy for the Treatment of Fibrosis
Application:
61/384,076 →
Bisphosphonate-Prostatic Acid Phosphatase Inhibitor Conjugates to Treat Prostate Cancer Bone Metastasis
Application:
12/883,662 →
Methods For Characterizing Antibody Binding Affinity And Epitope Diversity in Food Allergy
Application:
12/880,841 →
SHOC2 Mutations Causing Noonan-Like Syndrome With Loose Anagen Hair
Application:
12/775,396 →
Kruppel-like factor 6 (KLF6), a tumor suppressor protein, and diagnostics, therapeutics, and screening based on this protein
Application:
12/769,595 →
Nucleic Acids, Methods and Kits for the Diagnosis of DYT6 Primary Torsion Dystonia
Application:
12/694,908 →
Methods and Compositions for Treatment of Fibrosis
Application:
12/570,871 →
Mutations in Capillary Morphogenesis Gene-2 (Cmg-2) and Use Thereof
Application:
12/537,865 →
KLF6 Alternative Splice Forms and a Germline KLF6 Dna Polymorphism Associated with Increased Cancer Risk
Application:
11/572,645 →
Transgenic Oncolytic Viruses and Uses Thereof
Application:
12/520,571 →
Inhibition of Tumor Growth and Metastasis by ATF2-Derived Peptides
Application:
11/577,489 →
Method for Extending Longevity Using NPC1L1 Antagonists
Application:
11/997,600 →
Myeloid Suppressor Cells, Methods For Preparing Them, and Methods For Using Them For Treating Autoimmunity
Application:
12/159,929 →
Methods to Analyze Biological Networks
Application:
11/997,632 →
Resonance Energy Transfer System and Method
Application:
11/576,375 →
Inhibition of ATF2 Activity to Treat Cancer
Application:
11/945,133 →
Compositions and Methods for Altering Wnt Autocrine Signaling
Application:
11/719,327 →
Surrogate cell gene expression signatures for evaluating the physical state of a subject
Application:
10/558,277 →
Peptides for Treating Axonal Damage, Inhibition of Neurotransmitter Release and Pain Transmission, and Blocking Calcium Influx in Neurons
Application:
10/561,015 →
Viral Vectors With Improved Properties
Application:
10/558,394 →
Treatment of cancer by simultaneous inhibiton of BRAF and restoration or mimicry of p16INK4A activity
Application:
11/270,796 →
Compositions and Methods for Treating Alzheimer's Disease and Related Disorders and Promoting a Healthy Nervous System
Application:
11/255,780 →
Differential diagnosis of cancer and other conditions based on expression of p63
Application:
11/236,310 →
Treatment of Hepatic Fibrosis with Imatinib Mesylate
Application:
11/002,715 →
Chaperone-Based Therapy for Niemann-Pick Disease
Application:
10/998,270 →
Hybrid Fusion Protein Transcription Regulator to Induce Interferon Target Gene Expression
Application:
10/492,043 →
Endoluminal Colostomy System and Procedure
Application:
10/798,246 →
PTPN11 (Shp-2) Mutations and Cancer
Application:
10/703,210 →
Methods of Diagnosing Noonan Syndrome
Application:
10/262,552 →
Inhibition of ATF2 Activity to Treat Cancer
Application:
10/076,905 →
Differential Diagnosis of Cancer and Other Conditions Based on Expression of P63
Application:
10/043,502 →
Method and Device for Preventing Contrast Associated Nephropathy
Application:
09/757,301 →